VEGFA and lung adenocarcinoma: The anti-stromal IPF treatment nintedanib, which targets FGF, VEGF, and PDGF signaling, has been approved as a second-line therapy in lung adenocarcinoma as it has demonstrated greater clinical benefit in adenocarcinoma than in the SqCC histological subtype.